optalgin teva

Read More
Less
Teva CEO

Teva's new migraine drug helps contain profit fall

Teva has reduced its spending by $2.5 billion since initiating the restructuring last year.

By REUTERS
05/05/2019
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy